Stay updated with breaking news from Laxminarayan Bhat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an interview with HCPLive, Larry Ereshefsky, PharmD discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-s...
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Treatment with brilaroxazine was associated with clinically meaningful reductions in all major symptom domains in adults with schizophrenia.